BG Medicine Announces Issuance of Patent Covering Galectin-3 Testing for Cardiac Resynchronization Therapy
March 20, 2014 08:00 ET
|
BG Medicine, Inc.
WALTHAM, Mass., March 20, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced that on March 18, 2014, the United States Patent and Trademark Office issued patent 8,672,857, titled...
BG Medicine Reports 2013 Fourth Quarter and Year End Financial Results
March 20, 2014 07:50 ET
|
BG Medicine, Inc.
WALTHAM, Mass., March 20, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today reported financial results for the three months ended and year...
BG Medicine Announces Fiscal Year 2013 Financial Results Release Date and Conference Call Information
March 13, 2014 16:47 ET
|
BG Medicine, Inc.
WALTHAM, Mass., March 13, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced that the company will host a conference call and webcast on Thursday, March 20, 2014 at 8:30 a.m....
BG Medicine Welcomes La Jolla Pharmaceutical Company's Announcement of Positive Top-Line Results of Phase 2 Clinical Trial of Novel Pharmaceutical Compound Targeting Galectin-3 in Chronic Kidney Disease
March 12, 2014 08:30 ET
|
BG Medicine, Inc.
WALTHAM, Mass., March 12, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) welcomed today an announcement by La Jolla Pharmaceutical Company (LJPC) on March 10, 2014 of positive top-line...
BG Medicine Compliant With NASDAQ Listing Requirements
March 11, 2014 18:01 ET
|
BG Medicine, Inc.
WALTHAM, Mass., March 11, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) (the "Company") today announced that it has received correspondence from The NASDAQ Stock Market LLC ("NASDAQ")...
BG Medicine Welcomes Inclusion of Galectin-3 in 2014 Indian Consensus Document on Cardiac Biomarkers
March 10, 2014 08:30 ET
|
BG Medicine, Inc.
WALTHAM, Mass., March 10, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today that galectin-3 testing has been recognized for the first time in the newly issued 2014 Indian...
Automated VIDAS(R) Galectin-3 Assay Validated in Published Clinical Research Study
January 28, 2014 08:30 ET
|
BG Medicine, Inc.
WALTHAM, Mass., Jan. 28, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, welcomed today the publication of results of a clinical research...
BG Medicine to Transfer to the NASDAQ Capital Market; Obtains Requested NASDAQ Extension
January 27, 2014 08:30 ET
|
BG Medicine, Inc.
WALTHAM, Mass., Jan. 27, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) (the "Company") announced today that the NASDAQ Listing Qualifications Panel (the "Panel") has granted the Company's...
BG Medicine Welcomes Final Determination by CMS of 2014 Reimbursement for BGM Galectin-3(R) Test
December 10, 2013 08:30 ET
|
BG Medicine, Inc.
WALTHAM, Mass., Dec. 10, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today that the Centers for Medicare and Medicaid Services (CMS) have published the final determination of...
Independent Multicenter Trial Demonstrates Utility of BGM Galectin-3(R) Test for Accurately Classifying Risk of Unplanned Hospital Readmissions and Adverse Outcomes in Patients With Heart Failure
November 19, 2013 08:30 ET
|
BG Medicine, Inc.
WALTHAM, Mass., Nov. 19, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today the publication of results of an independent multicenter clinical research trial in Europe that...